Cagrilintide is Novo Nordisk's long-acting amylin analog. The drug is being developed both as monotherapy and — more notably — as the amylin component of CagriSema, the cagrilintide + semaglutide fixed-combination obesity drug.
The REDEFINE-1 and REDEFINE-2 Phase 3 trials read out across 2025 and 2026 with weight-loss data positioning CagriSema as a credible challenger to tirzepatide on combined-mechanism efficacy. Cagrilintide alone has shown standalone weight-loss effects, and amylin biology is the next obvious add-on layer to GLP-1 therapy after GIP and glucagon.
Stories here cover REDEFINE readouts, the regulatory path for combination peptide drugs, and the broader amylin pipeline (eloralintide, petrelintide). See #cagrisema, #amylin, and #novo-nordisk.
A second body-composition substudy from REDEFINE 1 presented May 14 at ECO 2026 broke out the DXA subgroup by treatment arm. At week 68, CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) produced -23.9% weight reduction in the DXA subgroup, compared with -16.6% on semaglutide 2.4 mg alone, -15.0% on cagrilintide 2.4 mg alone, and -2.8% on placebo. The fat-mass-to-lean-tissue ratios were favorable across all active arms: 66.9% fat-mass contribution on CagriSema, 69.7% on semaglutide, 62.9% on cagrilintide. The cagrilintide monotherapy arm is the first head-to-head body-composition signal for amylin-only therapy at clinically meaningful weight-loss levels — relevant to Zealand and Roche's petrelintide Phase 3 program and the broader amylin-versus-incretin debate.
A prespecified body-composition substudy of REDEFINE 1 presented at ECO 2026 reported that 252 participants on CagriSema 2.4 mg/2.4 mg (semaglutide + cagrilintide) achieved a 35.7% relative reduction in fat mass and a 14.4% reduction in lean soft-tissue mass at week 68 — compared with 5.7% and 4.3% on placebo. The headline 22.7% mean weight reduction in REDEFINE 1 (NEJM publication June 2025) thus broke down with a fat-mass-to-lean-tissue ratio of roughly 2.5:1, a more favorable body-composition profile than the typical 1.5-2:1 ratio reported for GLP-1 monotherapy. The data builds the case for combination amylin-GLP-1 therapy as preferentially fat-selective.
Novo Nordisk confirmed in its Q1 2026 commentary that a higher-dose CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) Phase 3 trial will start in the second half of 2026, in response to the February 23 readout where the lower-dose 2.4/2.4 mg arm achieved 23% mean weight loss vs. 25.5% on tirzepatide 15 mg over 84 weeks — failing the non-inferiority primary endpoint. The original CagriSema FDA filing is already submitted with a decision expected in late 2026; the higher-dose program is meant to position Novo for a more competitive head-to-head against tirzepatide before the retatrutide TRIUMPH readouts arrive. ECO 2026 in Istanbul (May 12–15) will deliver additional CagriSema data alongside Wegovy 7.2 mg.
Novo Nordisk announced April 28 that it will present 52 abstracts at the European Congress on Obesity (ECO 2026, Istanbul, May 12–15), including new data from the REDEFINE 1 trial of CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg): body composition and muscle strength, achievement of BMI/waist-to-height ratio targets, and cardiovascular risk reduction. Additional presentations will cover higher-dose Wegovy (semaglutide 7.2 mg), the Wegovy pill (oral semaglutide 25 mg) from OASIS 4 and ORION trials, and obesity treatment outcomes in women. The disclosure sets up a significant amylin/GLP-1 combination data event exactly as Zealand and Roche's amylin-only petrelintide moves into Phase 3.
Novo Nordisk's long-acting amylin analog produced significant weight loss as standalone treatment in a 68-week double-blind trial, strengthening its profile ahead of the CagriSema FDA decision.
Industry analysis highlights CagriSema (cagrilintide + semaglutide) Phase 3 data showing 14.2% weight loss in type 2 diabetes adults, positioning it as a major Novo Nordisk pipeline asset.
Novo Nordisk's amylin analog peptide showed significant weight loss as standalone treatment in Phase 3 trial data, positioning it as a new pillar in peptide-based obesity treatment.
Phase 3 trial results show cagrilintide, an amylin analogue peptide, achieved significant weight loss as a standalone therapy — a new peptide-based approach distinct from GLP-1 agonists.